Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The role of gonadotropin-releasing hormone antagonists in in vitro fertilization
Autore:
Diedrich, K; Ludwig, M; Felberbaum, RE;
Indirizzi:
Med Univ Lubeck, Dept Obstet & Gynecol, D-23538 Lubeck, Germany Med Univ Lubeck Lubeck Germany D-23538 Gynecol, D-23538 Lubeck, Germany
Titolo Testata:
SEMINARS IN REPRODUCTIVE MEDICINE
fascicolo: 3, volume: 19, anno: 2001,
pagine: 213 - 220
SICI:
1526-8004(200109)19:3<213:TROGHA>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN MENOPAUSAL GONADOTROPIN; OVARIAN STIMULATION; GNRH ANTAGONIST; ASSISTED REPRODUCTION; AGONIST TRIPTORELIN; PHASE-III; CETRORELIX; CYCLES; HMG; OVULATION;
Keywords:
GnRH-antagonists; premature luteinization; OHSS; Cetrorelix; Ganirelix;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Felberbaum, RE Med Univ Lubeck, Dept Obstet & Gynecol, Ratzeburger Allee 160, D-23538 Lubeck, Germany Med Univ Lubeck Ratzeburger Allee 160 Lubeck Germany D-23538
Citazione:
K. Diedrich et al., "The role of gonadotropin-releasing hormone antagonists in in vitro fertilization", SEMIN REP M, 19(3), 2001, pp. 213-220

Abstract

Gonadotropin-releasing hormone (GnRH)-antagonists can suppress the pituitary hormone secretion completely within a few hours, allowing the avoidance of premature luteinization within controlled ovarian hyperstimulation (COH)for assisted reproductive technologies (ART) by midcycle administration. Two different protocols were described, which were widely used in COH in several phase II and III studies as well as in clinical practice since the GnRH -antagonists Cetrorelix (Cetrotide(R); Serono International S.A., Geneva,Switzerland) and Ganirelix (Orgalutan(R), Antagon(R); Organon, Oss, The Netherlands) are available on the market. Cetrorelix was applied in single- and multiple-dose protocols; Ganirelix was used until now only according to the multiple-dose protocol. Fertilization rates of >60% as well as clinicalpregnancy rates of about 30% per transfer sound most promising. Estradiol secretion is not compromised by the GnRH-antagonists using recombinant follicle-stimulating hormone (FSH) for COH. The incidence of a premature leutinizing hormone (LH) surge is far below 2% while the pituitary response remains preserved, allowing the induction of ovulation by GnRH or GnRH-agonists. However, luteal phase support remains mandatory. The incidence of severe ovarian hyperstimulation syndrome (OHSS) seems to be lower under antagonist treatment than in the long agonistic protocol. Treatment time is significantly shortened. Without any doubt GnRH-antagonists have the potential to become the new standard for controlled ovarian hyperstimulation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 20:23:49